Entag, Joneson B.
HRN: 22-31-86 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/13/2022
CLINDAMYCIN 150MG/ML, 4ML (AMP)
12/13/2022
12/19/2022
IVT
600mg
Q6
Non Healing Wound (parietal Area); T/c Squamous Cell Carcinoma
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes